Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fangxin Hong

Showing results (61-70 of 101) with videos related to

Pageof 11
Sort By:
Nature|March 3, 2022
Silent mutations reveal therapeutic vulnerability in RAS Q61 cancersYoshihisa Kobayashi, Chhayheng Chhoeu, Jiaqi Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 18, 2013
Electronic self-report assessment for cancer and self-care support: results of a multicenter randomized trialDonna L Berry, Fangxin Hong, Barbara Halpenny, et al.
Journal of Pain and Symptom Management|December 18, 2021
Clinical Decision Support for Symptom Management in Lung Cancer Patients: A Group RCTMary E Cooley, Emanuele Mazzola, Niya Xiong, et al.
Cancer|June 29, 2016
Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496)Stefan K Barta, Hailun Li, Howard S Hochster, et al.
British Journal of Haematology|December 18, 2012
Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational studyRachel Rosovsky, Fangxin Hong, Deanna Tocco, et al.
BMC Medical Informatics and Decision Making|January 11, 2019
Assigning value to preparation for prostate cancer decision making: a willingness to pay analysisLeslie S Wilson, Traci M Blonquist, Fangxin Hong, et al.
Journal for Immunotherapy of Cancer|August 6, 2020
Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance statusJoao V Alessi, Biagio Ricciuti, Elizabeth Jiménez-Aguilar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2010
Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemiaIrene M Ghobrial, Fangxin Hong, Swaminathan Padmanabhan, et al.
Plos Genetics|February 6, 2008
Network discovery pipeline elucidates conserved time-of-day-specific cis-regulatory modulesTodd P Michael, Todd C Mockler, Ghislain Breton, et al.
Blood|September 6, 2012
Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trialKing L Tan, David W Scott, Fangxin Hong, et al.
Pageof 11

Showing results (61-70 of 101) with videos related to

Sort By:
Pageof 11
Nature|March 3, 2022
Silent mutations reveal therapeutic vulnerability in RAS Q61 cancersYoshihisa Kobayashi, Chhayheng Chhoeu, Jiaqi Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 18, 2013
Electronic self-report assessment for cancer and self-care support: results of a multicenter randomized trialDonna L Berry, Fangxin Hong, Barbara Halpenny, et al.
Journal of Pain and Symptom Management|December 18, 2021
Clinical Decision Support for Symptom Management in Lung Cancer Patients: A Group RCTMary E Cooley, Emanuele Mazzola, Niya Xiong, et al.
Cancer|June 29, 2016
Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496)Stefan K Barta, Hailun Li, Howard S Hochster, et al.
British Journal of Haematology|December 18, 2012
Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational studyRachel Rosovsky, Fangxin Hong, Deanna Tocco, et al.
BMC Medical Informatics and Decision Making|January 11, 2019
Assigning value to preparation for prostate cancer decision making: a willingness to pay analysisLeslie S Wilson, Traci M Blonquist, Fangxin Hong, et al.
Journal for Immunotherapy of Cancer|August 6, 2020
Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance statusJoao V Alessi, Biagio Ricciuti, Elizabeth Jiménez-Aguilar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2010
Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemiaIrene M Ghobrial, Fangxin Hong, Swaminathan Padmanabhan, et al.
Plos Genetics|February 6, 2008
Network discovery pipeline elucidates conserved time-of-day-specific cis-regulatory modulesTodd P Michael, Todd C Mockler, Ghislain Breton, et al.
Blood|September 6, 2012
Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trialKing L Tan, David W Scott, Fangxin Hong, et al.
Pageof 11